All Fulcrum Publications

April 4, 2022

A phase 2, randomized, double-blind, placebo-controlled, 48-Week study of the efficacy and safety of losmapimodin subjects with FSHD: ReDUX4

Christopher Morabito, MD, CMO

April 4, 2022

An Open-Label Study of Losmapimod to Evaluate the Safety, Tolerability, and Biomarker and Clinical Outcome Assessment Changes in Subjects with FSHD1

Joost Kools, Nicol Voermans, Karlien Mul, Lucienne Ronco, John Jiang, Jennifer Shoskes, Kelly Marshall, Diego Cadavid, Michelle L. Mellion, Baziel van Engelen

April 4, 2022

Quantitative MuscleAnalysis in FSHD Using Whole-Body MRI: Composite Muscle Measurements for Cross-Sectional Analysis

Per Widholm, Markus Karlsson, André Ahlgren, Olof Dahlqvist-Leinhard, Rabi Tawil, Kathryn Wagner, Jeffrey Statland, Leo Wang, Perry Shieh, Baziel Van Engelen, Diego Cadavid, Lucienne Ronco, Adefowope Odueyungbo, Jay Han, Maya Hatch, Michelle L. Mellion

April 4, 2022

Reachable Workspace to Evaluate Efficacy of Losmapimodin Subjects with FSHD in Two Phase 2 Studies

Rabi Tawil, MD, Kathryn Wagner, MD, PhD, Jeffrey Statland, MD, Leo Wang, MD, PhD, Angela Genge, MD, Sabrina Sacconi, MD, PhD, Hanns Lochmüller, MD, PhD, David Reyes Leiva, MD, Jordi Diaz-Manera, MD, PhD, Nuria Muelas, MD, PhD, Juan J. Vilchez, MD, PhD, Alan Pestronk, MD, Summer Gibson, MD, Namita A. Goyal, MD, Johanna Hamel, MD, Jay Han, MD, Lawrence Hayward, MD, Nicholas Johnson, MD, Samantha LoRusso, MD, Miriam Freimer, MD, Perry B. Shieh, MD, PhD, Sankarasubramoney H. Subramony, MD, Doris Leung MD, PhD, Baziel van Engelen MD, PhD, Joost Kools, MD, John Jiang, PhD, L. Alejandro Rojas, PhD, Anthony Accorsi, PhD,Christopher Morabito, MD, Jennifer Shoskes, PharmD, Michelle L. Mellion, MD (first author)

April 4, 2022

Whole Body MRI Quantitative muscle analysis to evaluate Efficacy of Losmapimodin a Phase 2 Placebo-Controlled Study in Subjects with FSHD (ReDUX4): ReDUX4 (NCT04003974)

Rabi Tawil, MD, Kathryn Wagner, MD, PhD, Jeffrey Statland, MD, Leo Wang, MD, PhD, Angela Genge, MD, Sabrina Sacconi, MD, PhD, Hanns Lochmüller, MD, PhD, David Reyes Leiva, MD, Jordi Diaz-Manera, MD, PhD, Jorge Alonso-Perez, MD, Nuria Muelas, MD, PhD, Juan J. Vilchez, MD, PhD, Alan Pestronk, MD, Summer Gibson, MD, Namita A. Goyal, MD, Johanna Hamel, MD, Lawrence Hayward, MD, Nicholas Johnson, MD, Samantha LoRusso, MD, Miriam Freimer, MD, Perry B. Shieh, MD, PhD, Sankarasubramoney H. Subramony, MD, Doris Leung MD, PhD, Baziel van Engelen MD, PhD, Joost Kools, MD, Olof Dahlqvist, Per Widholm, John Jiang, PhD, Adefowope Odueyungbo, PhD, William Tracewell, PhD, Alisa Rahilly, BSc, L. Alejandro Rojas, PhD, Anthony Accorsi, PhD, Steve Mennen, PhD, Lucienne Ronco, PhD, Diego Cadavid, MD, Christopher M. Moxham, PhD, Christopher Morabito, MD, Robert Gould, PhD, Michelle L. Mellion, MD.

March 16, 2022

Annualized Rates of Change from A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 48-Week Study of Losmapimod in Subjects with FSHD: ReDUX4

Rabi Tawil, MD

March 16, 2022

Functional validation of macrophage subtypes and co-culture models to identify targets in the inflammatory muscle microenvironment

Kelsey DeGouveia, Genevieve Wilson, Richard Lieberman, Eliza Eldredge, Anthony Accorsi

March 16, 2022

Identifying Targets to Inhibit Dystrophic Adipogenic Differentiation of Fibro-Adipogenic Progenitors via a Small Molecule Screen

Aidan Bailey, Genevieve Wilson, Richard Lieberman, Johnny Lucas, Joseph Maglio, Erin Valentine, Anthony Accorsi

March 16, 2022

Targeting Pathogenic Fibro-Adipogenic Progenitor Cell Differentiation to Promote Muscle Repair

Genevieve Wilson, Alexandria Taylor, Suchi Raghunathan, David Matson, Ivan Efremov, Eliza Eldredge, Anthony Accorsi

March 16, 2022

Reachable Workspace to Evaluate Efficacy of Losmapimod in Subjects with FSHD in Two Phase 2 Studies

Joost Kools, Nicol Voermans, Karlien Mul, Baziel van Engelen, Michelle L. Mellion, John Jiang, Jennifer Shoskes, Kelly Marshall, David Jackson, Yuxi Zhao, Anil Tarachandani, Joanita Figueredo, Damien Eggenspieler